Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roklatan. The company mainly operates in North America.

Investing News NetworkYour trusted source for investing success

Could the Silver Price Really Hit US$100 per Ounce? (Updated 2024)

Trump and the Gold Standard (Updated 2024)

7 Biggest Lithium-mining Companies

Top 10 Copper-producing Companies (Updated 2024)

How Would a New BRICS Currency Affect the US Dollar? (Updated 2024)

Uranium Stocks: 5 Biggest Companies in 2024

When Will Copper Go Up? (Updated 2024)

Hydrogen Stocks: 9 Biggest Companies

Where Does Tesla Get its Lithium? (Updated 2024)

Galan Increases Total Mineral Resource by 18% to 8.6Mt LCE @ 859mg/L Lithium

Canadian North Resources Inc. Provides an Update on its Metallurgical Testing Programs at the Ferguson Lake Project

CleanTech Lithium - CEOL Applications

Helium Evolution Confirms Additional Drilling of Up to 9 New Wells on Joint Land and Provides Operations Update

Lancaster Resources Closing of Spin-Off of Nelson Lake Copper Corp.

Operational and Financial Update

Fireweed Metals

Galan Lithium

Elixir Energy

RecycLiCo Battery Materials

2024 Rare Earths Outlook: Australia Edition

2024 Copper Outlook Report

2024 Battery Metals Outlook: Australia Edition

Nickel Investor Report

First Parcel of Ore for 2024 to be Processed Mid-April

Health House Australia and Corporate Update

Gold and Nickel Exploration Update

Deep Drilling Hits Visible Gold Over 1km Deep Below Never Never Gold Deposit

Sona Nanotech Secures Grant Funding to Support Intellectual Property Strategy and Development

Aerie Pharmaceuticals Inc.